King's College London

TY - JOUR

T1 - Inhaled nitric oxide for preventing prematurity-related bronchopulmonary dysplasia: seven-year follow-up of the EUNO trial

T2 - Long-term effects of inhaled nitric oxide

AU - Greenough, Anne

AU - Decobert, Fabrice

AU - Field, David

AU - Hallman, Mikko

AU - Hummler, Helmut

AU - Jonsson, Baldvin

AU - Sanchez Luna, Manuel

AU - Van Overmeire, Bart

AU - Carnielli, Virgilio

AU - Potenziano,, Jim

AU - Mercier, Jean-Christophe

PY - 2020

Y1 - 2020

N2 - Background: Most studies of inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in premature infants have focused on short term mortality and morbidity. Our aim was to determine the long-term effects of iNO.Methods: A seven-year follow-up was undertaken of infants entered into a multicenter, double-blind, randomized, placebo-controlled trial of iNO for prevention of BPD in premature infants born between 24 and 28 weeks plus 6 days of gestation. At seven years, survival and hospital admissions since the two-year follow-up, home oxygen therapy in the past year, therapies used in the previous month and growth assessments were determined. Questionnaires were used to compare general health, well-being, and quality of life. Results: Three hundred and five children were assessed. No deaths were reported. Rates of hospitalization for respiratory problems (6.6% vs 10.5%, iNO and placebo group, respectively) and use of respiratory medications (6.6% vs 9.2%) were similar. Two patients who received iNO and one who received placebo had received home oxygen therapy. There were no significant differences in any questionnaire-documented health outcomes. Conclusions: iNO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae. In the light of current evidence, routine use of iNO cannot be recommended for prevention of BPD in preterm infants.

AB - Background: Most studies of inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in premature infants have focused on short term mortality and morbidity. Our aim was to determine the long-term effects of iNO.Methods: A seven-year follow-up was undertaken of infants entered into a multicenter, double-blind, randomized, placebo-controlled trial of iNO for prevention of BPD in premature infants born between 24 and 28 weeks plus 6 days of gestation. At seven years, survival and hospital admissions since the two-year follow-up, home oxygen therapy in the past year, therapies used in the previous month and growth assessments were determined. Questionnaires were used to compare general health, well-being, and quality of life. Results: Three hundred and five children were assessed. No deaths were reported. Rates of hospitalization for respiratory problems (6.6% vs 10.5%, iNO and placebo group, respectively) and use of respiratory medications (6.6% vs 9.2%) were similar. Two patients who received iNO and one who received placebo had received home oxygen therapy. There were no significant differences in any questionnaire-documented health outcomes. Conclusions: iNO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae. In the light of current evidence, routine use of iNO cannot be recommended for prevention of BPD in preterm infants.

M3 - Article

JO - Journal of Perinatal Medicine

JF - Journal of Perinatal Medicine

SN - 0300-5577

ER -